COVID-19 Vaccine Payment Codes Released; ‘Specificity’ Will Help Real World Tracking
Executive Summary
American Medical Association announces reimbursement codes for the COVID-19 vaccines being developed by Pfizer/BioNTech and Moderna.
You may also be interested in...
The World Celebrates Pfizer's 90% COVID-19 Vaccine Efficacy Data, With Cautious Caveats
Pfizer's vaccine for COVID-19 outpaced expectations on efficacy, driving a stock market rally and garnering reaction from Vice President Pence and President-elect Biden.
Medicare Coverage Policy For COVID Drugs Underscores Importance Of Add-On Payments
Part of a broad rule that also aims to fix a coverage gap for COVID-19 vaccines, the payment policy differs from NTAP in that manufacturers of COVID therapies won’t have to formally apply and the add-on payments will not take the cost of the COVID products into account.
Real-World Evidence: CDC Prioritizing Populations, Outcomes For COVID-19 Vaccine Effectiveness Studies
Strategy for assessing how the earliest vaccines to reach market perform beyond clinical trials includes leveraging existing surveillance and data platforms, and employing a diversity of study approaches, CDC epidemiologist says; high-priority areas for study include protection against symptomatic illness among health care workers and prevention of severe disease in the elderly.